PD1-1-1 Phase Ib study of BI 836880 (VEGF/Ang2 nanobody®) plus ezabenlimab (BI 754091, anti-PD-1 antibody) in patients with solid tumorsNicolas Girard,Martin Wermke,Fabrice Barlesi,Dong-Wan Kim,Francois Ghiringhelli,Jaafar Bennouna,Thierry Lesimple,Enriqueta Felip,David Berz,Jong-Seok Lee,Harald Timotheus Landsteiner,Victoria Chen,Girish Jayadeva,Jurgen Alt,Bjorn HackansonAnnals of Oncology（2021）引用 4|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
